Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: denosumab

Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

Scott Baltic  |  August 19, 2017

NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report. Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb),…

Filed under:ConditionsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:bisphosphonatesbone mineral density (BMD)Osteoporosisosteoporosis treatmentsRheumatoid Arthritis (RA)teriparatideteriparatide treatment for osteoporosisWomen

Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2017

Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…

Filed under:Drug UpdatesResearch Rheum Tagged with:abataceptabuseAddictionApprovalsClinicalDrugsEndo PharmaceuticalsFDAMedicationOpana ERopioidoxymorphone hydrochloride extended releasepainkillerResearchresultsSafetytopical diclofenac sodiumtrialupadacitinib

Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients

Will Boggs, MD  |  April 11, 2017

NEW YORK (Reuters Health)—There are insufficient data to make evidence-based decisions regarding the benefits and harms of osteoporosis medications in patients with chronic kidney disease (CKD), according to a systematic review and meta-analysis. “We found low to moderate evidence for the effects of some but not all of the medications, and the evidence was limited…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:biophosphonatesbone mineral density (BMD)chronic kidney diseasedenosumabkidneyOsteoporosisosteoporosis treatments

A New Approach to Fracture Prevention

Susan Bernstein  |  December 14, 2016

Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetingdraft clinical guidelinefracture risk factorsFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoid-Induced Osteoporosis Prevention and Treatment: An Updated ACR Clinical GuidelineGlucocorticoidsOsteoporosis

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  October 19, 2016

The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabGlucocorticoid-Induced OsteoporosisGlucocorticoidsOsteoporosisproton pump inhibitor (PPI)

Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis

Rita Buckley  |  March 25, 2016

NEW YORK (Reuters Health)—The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Dr. Joy Tsai, from Massachusetts General Hospital in Boston, and colleagues conducted a single-site, two-year, open-label, randomized controlled trial involving 94 women aged 45 or older…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)combination therapydenosumabOsteoporosisosteoporosis treatmentspostmenopauseWomen

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting. The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsResearch RheumSystemic Sclerosis Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)auto-inflammatory diseasebisphosphonatesImmunologyOsteoporosisResearchSclerodermaTreatment

The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2016

The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…

Filed under:Biologics/DMARDsDrug Updates Tagged with:American College of Rheumatology (ACR)BiosimilarsFDAFood and Drug AdministrationinfliximabromosozumabTofacitinibtofacitinib citrate

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  October 13, 2015

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Growth Hormone Reduces Fractures in Women with Osteoporosis

Will Boggs, MD  |  September 4, 2015

NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Growth HormoneOsteoporosispostmenopauseWomen

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences